The estimated Net Worth of Cell Therapeutics, Inc. Lin... is at least 35 百万$ dollars as of 2 January 2020. Cell Lin owns over 2,383,090 units of Oncocyte stock worth over 18,727,577$ and over the last 5 years Cell sold OCX stock worth over 16,287,474$.
Sign up
Cell Lin OCX stock SEC Form 4 insiders trading
Cell has made over 3 trades of the Oncocyte stock since 2019, according to the Form 4 filled with the SEC. Most recently Cell sold 2,383,090 units of OCX stock worth 5,147,474$ on 2 January 2020.
The largest trade Cell's ever made was selling 4,000,000 units of Oncocyte stock on 11 September 2019 worth over 6,640,000$. On average, Cell trades about 2,877,697 units every 60 days since 2019. As of 2 January 2020 Cell still owns at least 6,041,154 units of Oncocyte stock.
You can see the complete history of Cell Lin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Cell Lin's mailing address?
Cell's mailing address filed with the SEC is 2173 SALK AVENUE, SUITE 200, , CARLSBAD, CA, 92008.
Insiders trading at Oncocyte
Over the last 9 years, insiders at Oncocyte have traded over 16,389,842$ worth of Oncocyte stock and bought 56,056,405 units worth 102,313,246$ . The most active insiders traders include Partners, L.P.Broadwood Cap...、Cell Therapeutics, Inc. Lin...、Partners, L.P.Bradsher Neal.... On average, Oncocyte executives and independent directors trade stock every 37 days with the average trade being worth of 3,382,106$. The most recent stock trade was executed by Josh Riggs on 11 April 2024, trading 3,390 units of OCX stock currently worth 10,001$.
What does Oncocyte do?
oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.
What does Oncocyte's logo look like?
Complete history of Cell Lin stock trades at Oncocyte
Oncocyte executives and stock owners
Oncocyte executives and other stock owners filed with the SEC include:
-
Ronald Andrews,
President, Chief Executive Officer, Director -
Lyndal Hesterberg,
Chief Scientific Officer -
Mitchell Levine,
Chief Financial Officer -
Ronald A. Andrews Jr.,
CEO, Pres & Director -
Cavan Redmond,
Independent Chairman of the Board -
Andrew Last,
Independent Director -
Andrew Arno,
Independent Director -
Melinda Griffith,
Independent Director -
Bob Yedid,
Investor Relations -
Douglas Ross,
Chief Medical Officer -
Padma Sundar,
Senior Vice President - Marketing and Market Access -
Tony Kalajian,
Senior Vice President, Chief Accounting Officer -
Albert Parker,
Chief Operating Officer -
Dr. Michael D. West Ph.D.,
Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. -
Dr. Ekkehard Schutz M.D., Ph.D.,
Chief Technology Officer -
Robert S. Seitz,
Head of Immune Oncology -
Li Yu,
VP, Controller & Principal Accounting Officer -
Gisela A. Paulsen,
Chief Operating Officer -
Sara Riordan,
Director of Medical Education -
Dr. Michael D. West,
Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. -
Dr. Douglas T. Ross M.D., Ph.D.,
Chief Science Officer -
William Annett,
Advisor -
Gisela Paulsen,
Former President and COO -
Vida Investments, Llc Kamen...,
-
Karen B. Chapman,
Vice President of Research -
Alfred D Kingsley,
Director -
Don M Bailey,
Director -
William Annett,
President and CEO -
Michael D West,
Director -
Kristine C. Mechem,
VP of Marketing -
Partners, L.P.Broadwood Cap...,
-
Anish M. John,
Chief Financial Officer -
Aditya P. Mohanty,
Director -
Cell Therapeutics, Inc. Lin...,
-
James Yang Liu,
Sr Dir., Cntlr, PAO, Int PFO -
Jennifer L. Carter,
Director -
Li Yu,
VP Cntrllr/Prncpl Acctng Offcr -
Partners, L.P.Bradsher Neal...,
-
Lou Silverman,
Director -
Josh Riggs,
CEO and President -
John Peter Gutfreund,
-
Andrea S. James,
Chief Financial Officer